Spots Global Cancer Trial Database for relapsed and resistant classical hodgkin's disease
Every month we try and update this database with for relapsed and resistant classical hodgkin's disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease | NCT00129753 | Hodgkin's Disea... Lymphoma | Alemtuzumab (Ca... | 18 Years - | M.D. Anderson Cancer Center |